BUSINESS● LOW1h ago · Sep 8, 2026, 8:56 AM
Novartis drops 13% on trial failure, dragging Dyne and Sarepta
Seeking Alpha Tech · global
Novartis's stock dropped 13% due to a trial failure, also affecting Dyne and Sarepta. This event has significant financial implications for these pharmaceutical companies.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowBoeing, Airbus, Embraer… Who will benefit from the boom in African air traffic?Jeune AfriqueBUSINESS30m agoNigerian newspapers review: Foreign investors pull out N266bn from Nigeria in 3 yrsVanguard NigeriaBUSINESS40m agoGoldman sees oil upside capped as Gulf exports run above visible flowsSeeking Alpha TechBUSINESS43m agoChina car exports surge 78% as domestic sales slide for 11th monthSeeking Alpha Tech